<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Orthotopic, Bioluminescent Syngeneic HCC Models for Immunotherapy Assessment

Interrogation of Checkpoint Inhibitors in Bioluminescent Orthotopic Syngeneic Models of Hepatocellular Carcinoma

Nektaria Papadopoulou, Louise Wainwright, Vicky Lacey, Jane Wrigley, Jamie Wood, Sumanjeet Malhi, Louise Woolley, Jason King, Simon Jiang, and Rajendra Kumari

CrownBio 2017. Orthotopic, Bioluminescent Syngeneic HCC Models for Immunotherapy AssessmentThere are currently limited treatment options for hepatocellular carcinoma (HCC), which is a highly aggressive cancer type. While immunotherapies such as checkpoint inhibitors are being trialled clinically, suitable preclinical models are needed to optimise and speed their development.

Subcutaneous syngeneic models are the common preclinical choice to assess the impact of immunotherapy on tumour growth and tumour invading leucocytes; however, orthotopic models have a more relevant tumour microenvironment and are more closely comparable to patient disease factors.

CrownBio has therefore developed orthotopic, syngeneic HCC models which are also bioluminescent, which allows non-invasive and real time longitudinal monitoring of tumour burden, and assessment of checkpoint inhibitors to treat HCC.

Read this Poster to Discover:

  • The development and characterisation of Hepa 1-6 and H22 orthotopic, bioluminescent syngeneic models, with liver transplantation success rates of 70% and 100%, respectively
  • That Hepa 1-6-lux allografts grow in the parenchyma of the liver, with a significant reduction in tumour burden following sorafenib treatment
  • That H22-lux allografts develop in the liver, with malignant ascites in the peritoneum, with trends towards reduced tumour burden following sorafenib or anti-CTLA-4-treatment

Download the Poster Now!

Download Now

Your privacy is important to us.
We'll never share your information.